Zebra Biologics Inc., a Concord-based emerging pre-clinical biotechnology company, is collaborating with Worcester global biopharma AbbVie to discover agonist antibody therapies for inflammatory diseases.
Through the partnership, announced earlier this month, Zebra will use its novel and patented function-based antibody discovery platform to generate antibodies that activate biological pathways associated with AbbVie-designated targets.
Zebra will lead the discovery of candidate agonist antibodies for the targets, and collaborate with AbbVie in pre-clinical validation. Once clinical candidates are advanced, AbbVie will be responsible for clinical development, manufacturing, regulatory approval and commercialization.
